First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.
Jonathan Wade Goldman
Honoraria - Lilly
Research Funding - Lilly
Lee S. Rosen
Research Funding - Lilly
Alain Patrick Algazi
No relevant relationships to disclose
Patricia Kellie Turner
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Volker Wacheck
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Jay Tuttle
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
James E Wooldridge
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Michaela S. Banck
No relevant relationships to disclose